Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-A02574-41 | Other Identifier | ID-RCB number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.
The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.
The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.
Furthermore, two key aspects from a Public Health perspective are associated with travel and the globalization of exchanges: the acquisition of emerging pathogens or pathogens with antimicrobial resistance of concern.
To study these two aspects, the EOP study includes two sub-studies called EOP-Arbo and EOP-AMR.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adults planning to travel outside metropolitan France. | Experimental | Human biological samples :
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sample collection | Other | 16 mL at inclusion 16 mL at 1 month after return from travel |
|
| Measure | Description | Time Frame |
|---|---|---|
| Determine the incidence of pathologies occurring during a travel outside the metropolitan territory. | Number of subjects who developed a pathology during the travel among participants | 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| For EOP-Arbo sub-study : Determine the prevalence for the occurrence of an arboviral disease (dengue, chikungunya, Zika) during the travel. | Number of arboviral diseases (dengue, chikungunya, Zika) during the travel among participants | 10 years |
| For EOP-AMR sub-study : Determine the prevalence for the acquisition of multi-resistant bacteria (MRB) during the travel. |
Not provided
Inclusion Criteria :
For all participants in the EOP study :
For the EOP-Arbo Sub-study :
- Subject who has consented to participate in the EOP_Arbo study.
For the EOP-AMR Sub-study :
Exclusion Criteria:
For all participants in the EOP study :
For the EOP-Arbo Sub-study :
- Individuals deemed clinically and/or biologically unfit by the investigator to undergo the blood samples required for the study.
For the EOP-AMR Sub-study :
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Fabien TAIEB, MD | Contact | 0140613456 | +33 | fabien.taieb@pasteur.fr |
| Julia ABAD | Contact | julia.abad@pasteur.fr |
| Name | Affiliation | Role |
|---|---|---|
| Fabien TAIEB, MD | Medical Center of Institut Pasteur | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical Center of Institut Pasteur | Recruiting | Paris | 75015 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000076082 | Travel-Related Illness |
| ID | Term |
|---|---|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fecal sample collection | Other | 1 sample at inclusion 1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel |
|
Proportion of subjects with multi-resistant bacteria acquired during the travel |
| 10 years |